During the first pregnancy, the initial exposure to fetal RBCs results in the formation of IgM antibodies, and these do not cross the placental barrier , which is why no effects are seen in first pregnancies for Rh-D mediated disease. However, in subsequent pregnancies, the immune system mounts a memory response when re-exposed, and these antibodies IgG do cross the placenta into fetal circulation. These antibodies are directed against a protein found on the surface of the fetal red blood cells RBCs. The antibody coated fetal red blood cells are destroyed.
|Published (Last):||14 February 2006|
|PDF File Size:||10.33 Mb|
|ePub File Size:||6.14 Mb|
|Price:||Free* [*Free Regsitration Required]|
Anti-D immunoglobulin should be administered also to all RhDnegative women during pregnancy when there is an increased risk of fetomaternal bleeding. Routine use of anti-D immunoglobulin at 28 or 34 weeks of pregnancy for all Rh-negative women is of value as well, but the costs of such a programme are high and together with the limited supplies of anti-D immunoglobulin may preclude this in some countries.
Rhesus iso-immunization has become sufficiently rare, and the treatment sufficiently complex, to warrant regionalization of care for these women and babies. Hopefully, this may facilitate adequate evaluation of the methods used for diagnosis and treatment, none of which have been as yet subjected to controlled trials.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription. Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
Alloimmunisation fœto-maternelle Rhésus grave à propos d'un cas et revue de la littérature